Oxford BioDynamics Plc (OXBOF) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
$'dan işlem gören Oxford BioDynamics Plc (OXBOF), 0 değerindeki bir Healthcare şirketidir. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 49/100 (ihtiyatlı) olarak derecelendirilmiştir.
Son analiz: 17 Mar 2026Oxford BioDynamics Plc (OXBOF) Sağlık ve Boru Hattı Genel Bakışı
Oxford BioDynamics Plc leverages its EpiSwitch platform to discover and develop epigenetic biomarkers for disease prediction and treatment. The company operates in the biotechnology sector, offering diagnostic and prognostic tools like EpiSwitch CiRT and CST, primarily targeting the pharmaceutical and biotechnology industries internationally.
Yatırım Tezi
Oxford BioDynamics presents a high-risk, high-reward investment profile within the biotechnology sector. The company's proprietary EpiSwitch platform offers a unique approach to biomarker discovery with potential applications across various diseases. A key value driver is the successful commercialization of EpiSwitch CiRT, which could generate revenue through predicting patient response to immunotherapy. The company's ability to secure partnerships with pharmaceutical companies for biomarker discovery and drug development is also crucial. However, the company's negative profit and gross margins (-1018.5% and -561.6%, respectively) highlight financial challenges. Upcoming data releases from clinical studies using EpiSwitch and regulatory approvals for its diagnostic tests are potential catalysts. Investors should closely monitor the company's cash burn rate and ability to secure additional funding to sustain operations.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- EpiSwitch Platform: Proprietary technology for epigenetic biomarker discovery.
- EpiSwitch CiRT: Validated prognostic test for predicting response to checkpoint inhibitor immunotherapy.
- EpiSwitch CST: Advanced blood test for predicting COVID-19 severity in adults.
- Market Cap: $0.00B indicates the company is a micro-cap stock.
- Negative Profit Margin: -1018.5% signals significant losses and operational inefficiencies.
Rakipler & Benzerleri
Güçlü Yönler
- Proprietary EpiSwitch platform for epigenetic biomarker discovery.
- Validated diagnostic tests like EpiSwitch CiRT and CST.
- Expertise in epigenetics and biomarker development.
- Potential for partnerships with pharmaceutical companies.
Zayıflıklar
- Negative profit and gross margins.
- Limited commercialization of products.
- Dependence on external funding.
- OTC market listing indicates higher risk.
Katalizörler
- Upcoming: Data releases from clinical studies using EpiSwitch for biomarker discovery.
- Upcoming: Potential regulatory approvals for EpiSwitch CiRT and other diagnostic tests.
- Ongoing: Expansion of partnerships with pharmaceutical companies for drug development.
- Ongoing: Increasing adoption of EpiSwitch technology in personalized medicine.
- Ongoing: Development of new diagnostic tests for autoimmune diseases.
Riskler
- Ongoing: Negative profit and gross margins raise concerns about financial sustainability.
- Potential: Competition from established players in genomics and proteomics.
- Potential: Regulatory hurdles for diagnostic tests.
- Potential: Failure to secure additional funding.
- Ongoing: Limited liquidity due to OTC market listing.
Büyüme Fırsatları
- Expansion of EpiSwitch CiRT into new cancer types: The EpiSwitch CiRT test is currently focused on predicting response to checkpoint inhibitors in specific cancers. Expanding its application to other cancer types represents a significant growth opportunity. The global oncology market is projected to reach $286.6 billion by 2028, providing a large addressable market for CiRT and future diagnostic tests. Timeline: Ongoing clinical trials and validation studies are expected to support expansion over the next 2-3 years.
- Development of new diagnostic tests for autoimmune diseases: Autoimmune diseases represent a significant unmet medical need, and the EpiSwitch platform could be used to develop novel diagnostic tests. The global autoimmune disease diagnostics market is projected to reach $16.1 billion by 2027. Oxford BioDynamics could leverage its technology to capture a share of this market. Timeline: Research and development efforts are likely to span 3-5 years before a commercially viable product is available.
- Partnerships with pharmaceutical companies for drug development: Oxford BioDynamics can partner with pharmaceutical companies to use the EpiSwitch platform to identify biomarkers for drug development. This could generate revenue through licensing agreements, milestone payments, and royalties on sales of drugs developed using the company's biomarkers. The pharmaceutical industry spends billions of dollars annually on drug discovery and development, creating a substantial market for biomarker-based services. Timeline: Partnership agreements could be established within the next 1-2 years, with revenue generation dependent on the success of drug development programs.
- Geographic expansion into Asia and Europe: Oxford BioDynamics currently focuses on the United States and international markets. Expanding into Asia and Europe represents a growth opportunity, particularly in countries with advanced healthcare systems and a growing demand for personalized medicine. The Asia-Pacific diagnostics market is projected to be the fastest-growing region globally. Timeline: Expansion efforts could begin within the next 2 years, with a focus on establishing partnerships and distribution networks.
- Application of EpiSwitch technology to personalized medicine: The EpiSwitch platform can be used to develop personalized medicine approaches, tailoring treatment decisions to individual patients based on their epigenetic profiles. The personalized medicine market is growing rapidly, driven by advances in genomics and proteomics. Oxford BioDynamics can position itself as a leader in epigenetic-based personalized medicine. Timeline: Development of personalized medicine applications is a long-term effort, likely to span 5-10 years.
Fırsatlar
- Expansion of EpiSwitch CiRT into new cancer types.
- Development of new diagnostic tests for autoimmune diseases.
- Partnerships with pharmaceutical companies for drug development.
- Geographic expansion into Asia and Europe.
Tehditler
- Competition from established players in genomics and proteomics.
- Regulatory hurdles for diagnostic tests.
- Failure to secure additional funding.
- Uncertainty in the biotechnology industry.
Rekabet Avantajları
- Proprietary EpiSwitch platform: Provides a unique technology for epigenetic biomarker discovery.
- Validated diagnostic tests: EpiSwitch CiRT and CST have demonstrated clinical utility.
- Expertise in epigenetics: Oxford BioDynamics has a team of scientists with expertise in epigenetics and biomarker discovery.
- Partnerships with pharmaceutical companies: Provides access to resources and expertise for drug development.
OXBOF Hakkında
Oxford BioDynamics Plc, incorporated in 2007 and headquartered in Oxford, UK, is a biotechnology company specializing in the discovery and development of biomarkers. The company's core technology is EpiSwitch, a proprietary platform that identifies and validates chromosome conformation signatures for use as epigenetic biomarkers. These biomarkers are applied in medical testing kits, disease prediction, diagnosis, and treatment monitoring. The company's key products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a prognostic test designed to predict a patient's response to checkpoint inhibitor immunotherapy. Another product, EpiSwitch CST (Covid Severity Test), is a blood test aimed at predicting the severity of COVID-19 in adults. Additionally, Oxford BioDynamics offers the EpiSwitch Explorer Array Kit, which facilitates high-resolution 3D genome profiling and biomarker discovery. Oxford BioDynamics primarily serves the pharmaceutical and biotechnology industries, focusing on developing tools that can improve drug development, clinical trials, and patient outcomes. The company operates both in the United States and internationally, seeking partnerships and collaborations to expand the reach of its EpiSwitch technology and biomarker portfolio.
Ne Yaparlar
- Discovers epigenetic biomarkers using its proprietary EpiSwitch platform.
- Develops diagnostic and prognostic tests for various diseases.
- Offers the EpiSwitch CiRT test to predict response to cancer immunotherapy.
- Provides the EpiSwitch CST test for predicting COVID-19 severity.
- Offers the EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling.
- Partners with pharmaceutical companies for biomarker discovery and drug development.
İş Modeli
- Generates revenue through the sale of diagnostic and prognostic tests.
- Partners with pharmaceutical companies for biomarker discovery and drug development, earning licensing fees, milestone payments, and royalties.
- Offers services for high-resolution 3D genome profiling and biomarker discovery using the EpiSwitch Explorer Array Kit.
Sektör Bağlamı
Oxford BioDynamics operates within the competitive biotechnology industry, which is characterized by rapid innovation and high regulatory hurdles. The market for biomarker discovery and diagnostics is growing, driven by the increasing demand for personalized medicine and targeted therapies. Companies like Oxford BioDynamics face competition from established players in genomics and proteomics, as well as other emerging biotechnology firms. The company's success depends on its ability to differentiate its EpiSwitch platform, secure regulatory approvals, and establish partnerships with pharmaceutical companies.
Kilit Müşteriler
- Pharmaceutical companies seeking biomarkers for drug development.
- Biotechnology companies developing diagnostic and therapeutic products.
- Hospitals and clinics using diagnostic tests for patient care.
- Research institutions conducting studies on epigenetics and disease.
Finansallar
Grafik & Bilgi
Oxford BioDynamics Plc (OXBOF) hisse senedi fiyatı: Price data unavailable
Son Haberler
OXBOF için son haber bulunmamaktadır.
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
OXBOF için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
OXBOF için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, OXBOF'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Rakipler & Benzerleri
Yönetim: Iain Gladstone Ross
Managing Director
Iain Gladstone Ross serves as the Managing Director of Oxford BioDynamics Plc, overseeing the company's operations and strategic direction. Information regarding his detailed career history and educational background is not available in the provided data. However, as Managing Director, he is responsible for guiding the company's biomarker discovery and diagnostic development efforts.
Sicil: As Managing Director, Iain Gladstone Ross manages 51 employees. Specific achievements and milestones under his leadership are not detailed in the provided data. His role is crucial in driving the commercialization of the EpiSwitch platform and securing partnerships to advance the company's growth.
OXBOF OTC Piyasa Bilgileri
The OTC Other tier, where Oxford BioDynamics trades, represents the lowest tier of the OTC market. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, companies on the OTC Other tier often have limited financial disclosure requirements and may not meet minimum listing standards. This tier typically includes companies with higher risk profiles, including those that are thinly traded, distressed, or have limited operating history. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited financial disclosure: The lack of publicly available financial reports makes it difficult to assess the company's financial health.
- Low liquidity: Limited trading volume can lead to wider bid-ask spreads and greater price volatility.
- Higher risk of fraud or manipulation: OTC markets are subject to less regulatory oversight than major exchanges.
- Potential for delisting: Failure to meet minimum listing standards could result in delisting from the OTC market.
- Limited access to capital: OTC-listed companies may have difficulty raising capital through public offerings.
- Verify the availability of financial reports and assess the company's financial health.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Assess the liquidity of the stock and the potential for price volatility.
- Review the company's regulatory filings and compliance history.
- Consult with a financial advisor before investing.
- Confirm the legitimacy of the company's operations and assets.
- Proprietary EpiSwitch platform suggests technological innovation.
- Development of diagnostic tests like EpiSwitch CiRT and CST indicates potential for commercialization.
- Partnerships with pharmaceutical companies could validate the company's technology.
- Headquarters in Oxford, UK, a hub for biotechnology research.
- Management team with experience in the biotechnology industry.
OXBOF Healthcare Hisse Senedi SSS
OXBOF için değerlendirilmesi gereken temel faktörler nelerdir?
Oxford BioDynamics Plc (OXBOF) şu anda yapay zeka skoru 49/100, düşük puanı gösteriyor. Temel güçlü yan: Proprietary EpiSwitch platform for epigenetic biomarker discovery.. İzlenmesi gereken birincil risk: Ongoing: Negative profit and gross margins raise concerns about financial sustainability.. Bu bir finansal tavsiye değildir.
OXBOF MoonshotScore'u nedir?
OXBOF şu anda MoonshotScore'da 49/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
OXBOF verileri ne sıklıkla güncellenir?
OXBOF fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler OXBOF hakkında ne diyor?
OXBOF için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
OXBOF'a yatırım yapmanın riskleri nelerdir?
OXBOF için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Ongoing: Negative profit and gross margins raise concerns about financial sustainability.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
OXBOF'ın P/E oranı nedir?
OXBOF için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için OXBOF'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
OXBOF aşırı değerli mi, yoksa düşük değerli mi?
Oxford BioDynamics Plc (OXBOF)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
OXBOF'ın temettü verimi nedir?
Oxford BioDynamics Plc (OXBOF) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Financial data is limited and may not be up-to-date.
- Analyst consensus is not available.
- OTC market listing indicates higher risk.